At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
Avastin + mFOLFOX6drug
Likely dose
Avastin + mFOLFOX6 85 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Avastin + mFOLFOX6 for Metastatic Breast Cancer. Completed, enrolled 72 participants across 1 site.
Detailed Summary
The objective of this phase II study is to evaluate efficacy and safety of avastin plus modified FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients. Fifty-five patients will be enrolled into this study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Breast Cancer
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartMay 2012
First PostedAug 2012
Primary CompletionNov 2013
Study CompletionNov 2014
TodayJul 2026
First PostedAug 6, 2012
Enrollment StartMay 1, 2012
Primary CompletionNov 1, 2013
Study CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 13.9 years ago
Interventions
Avastin + mFOLFOX6drug
mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h； Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w